Determination of kinetic parameters and structure–activity relationships of ginsenosides as inhibitors of cyclin‐dependent kinase 5/p25 using ultra‐pressure liquid chromatography with triple quadrupole tandem mass spectrometry

Chen, Ning; Yang, Hongmei; Niu, Jun; Liu, Shuying

doi:10.1002/rcm.6537

Cited by 6 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PKA inhibition assay was carried out based on the method described by Chen et al. with some modifications. The incubation mixtures (final volume 50 μL) contained (final concentrations) 5 mM MgCl 2 , 0.5 mM DTT, 96 ng/mL PKA, 4 μM kemptide (PKA substrate), hesperetin, H‐7G, or H‐3′G added from a 100 times concentrated stock in DMSO (final concentration ranging from 0 to 500 μM) in 50 mM Tris‐HCl (pH 7.4).…”

Section: Methodsmentioning

confidence: 99%

Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans

Boonpawa

Spenkelink

Punt

et al. 2017

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans

Boonpawa

Spenkelink

Punt

et al. 2017

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

High‐Throughput Mass Spectrometry Complements Protein Engineering

Xue

Choe

et al. 2021

Protein Engineering

View full text Add to dashboard Cite

Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development

Cacabelos

Torrellas

et al. 2014

Methods in Molecular Biology

165

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a major problem of health and disability, with a relevant economic impact on our society. Despite important advances in pathogenesis, diagnosis, and treatment, its primary causes still remain elusive, accurate biomarkers are not well characterized, and the available pharmacological treatments are not cost-effective. As a complex disorder, AD is a polygenic and multifactorial clinical entity in which hundreds of defective genes distributed across the human genome may contribute to its pathogenesis. Diverse environmental factors, cerebrovascular dysfunction, and epigenetic phenomena, together with structural and functional genomic dysfunctions, lead to amyloid deposition, neurofibrillary tangle formation, and premature neuronal death, the major neuropathological hallmarks of AD. Future perspectives for the global management of AD predict that genomics and proteomics may help in the search for reliable biomarkers. In practical terms, the therapeutic response to conventional drugs (cholinesterase inhibitors, multifactorial strategies) is genotype-specific. Genomic factors potentially involved in AD pharmacogenomics include at least five categories of gene clusters: (1) genes associated with disease pathogenesis; (2) genes associated with the mechanism of action of drugs; (3) genes associated with drug metabolism (phase I and II reactions); (4) genes associated with drug transporters; and (5) pleiotropic genes involved in multifaceted cascades and metabolic reactions. The implementation of pharmacogenomic strategies will contribute to optimize drug development and therapeutics in AD and related disorders.

show abstract

Determination of kinetic parameters and structure–activity relationships of ginsenosides as inhibitors of cyclin‐dependent kinase 5/p25 using ultra‐pressure liquid chromatography with triple quadrupole tandem mass spectrometry

Abstract: The developed UPLC/TQMS-based method for determination of an inhibitor of cdk5/p25 is sensitive and reliable. The effect of ginsenosides on Alzheimer's disease may be involved with the regulation of activities of cdk5/p25.

Cited by 6 publications

References 40 publications

Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans

Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans

High‐Throughput Mass Spectrometry Complements Protein Engineering

Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development

Contact Info

Product

Resources

About